Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
- PMDA Evaluating Xtandi for Risk of Thrombocytopenia
September 30, 2014
- MHLW OKs 19 Products Including MSD’s Insomnia Drug Suvorexant
September 29, 2014
- Daclatasvir/Asunaprevir Combination Therapy for Hepatitis C Now Eligible for Medical Subsidy: MHLW
September 26, 2014
- Govt Panel Approves Plan for Special Zone in Kansai Area Where Mixed-Healthcare Using Unapproved Drugs Will Be Permitted
September 26, 2014
- Editor’s Pick: Five Healthcare News Headlines for September 8 – September 19
September 25, 2014
- Copayment Hike for New Drugs Up for Discussion towards Healthcare Overhaul
September 25, 2014
- MHLW Approves Additional Indications for Aricept, 2 Other Drugs
September 22, 2014
- MHLW Guidelines to Call for Thorough Internal Communications at Pharmas after Novartis’ Delayed ADR Reporting
September 19, 2014
- MHLW Official Concerned about Generic Codevelopment, but Denies Plans to Press for Industry Consolidation
September 19, 2014
- Selexipag, 4 Other APIs Designated as Orphan Drugs
September 19, 2014
- MHLW Launches Discussions on Requirements for Legally Backed Clinical Research Core Hospitals
September 17, 2014
- Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs
September 17, 2014
- MHLW Orders Revision of Package Insert for Lyrica
September 17, 2014
- PMDA Issues Alert on Administration of ARBs and ACE Inhibitors in Pregnant Women
September 12, 2014
- US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights
September 12, 2014
- EAD Director to Visit 5 Public Hospital Groups to Encourage Quick Settlement of Price Negotiations
September 12, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
- Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis
September 11, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…